Log in to your IBTimes Account

close
ID
Password

The serious allegations have sent Ranbaxy shares plummeting to a 7-year low close

US FDA accuses Ranbaxy Laboratories of fraud, concealment and selling substandard drugs



By Sakshi Ganguli
14 July 2008 @ 8:06 pm IST

New Delhi - The United States Food and Drug Administration (US FDA) has accused India's largest generics drug maker, Ranbaxy Laboratories, of forging and concealing documents relating to an investigation into the quality of the company's drugs sold in the US market and has filed a motion in the district court of Maryland seeking documents from the Indian firm.


Chief Executive Officer and Managing Director of Ranbaxy Laboratories Malvinder Singh answers a question during a press conference in New Delhi on June 11, 2008
Chief Executive Officer and Managing Director of Ranbaxy Laboratories Malvinder Singh answers a question during a press conference in New Delhi on June 11, 2008. The United States Food and Drug Administration (US FDA) has accused India`s largest generics drug maker, Ranbaxy Laboratories, of forging and concealing documents relating to an investigation into the quality of the company`s drugs sold in the US market and has filed a motion in the dist...
1 of 1

advertisement

Ranbaxy depends on the US market for 25 percent of its sales and the ongoing investigation is expected to sully its image in the market. Ranbaxy had global sales of $1.61 billion last year, including $386 million in the US.

The US Government has alleged that officials at Ranbaxy's plant in northern India had used raw pharmaceutical chemicals from unapproved sources, fabricated in-house test data to meet US FDA standards and attempted to conceal the fraud from FDA inspectors.

The "pattern of systemic fraudulent conduct," the government said in papers filed in district court, left an untold portion of the tablets and capsules made by Ranbaxy "subpotent, super potent or adulterated."

"The government has reason to believe that these violations have resulted and continue to result in the introduction of adulterated and misbranded products" into the US market, federal prosecutors said. The prosecutors have urged the court to force Ranbaxy to turn over an internal review of its manufacturing operations in India.

The charges are also expected to jeopardize the $4.6 billion acquisition agreement between Ranbaxy and its acquirer, Japanese drug firm Daiichi Sankyo.

Mamoru Tsunoda, spokesman for the Japanese drug maker, said the firm is closely watching the development and it is too early to say whether the firm would walk out of the deal.

"We would like to continue our work until the deal is closed while also keeping close eyes on what's going on between Ranbaxy and FDA," he said. However, the Japanese firm is expected to go for stringent due diligence before it goes ahead with the transaction.

A Ranbaxy spokesman said the company strongly denied any wrongdoing and would file a response in the court on Monday.

"An investigation has been underway for approximately three years. Despite this, no charges have been filed. During this period, Ranbaxy has been cooperating fully with the Department of Justice. We've been conscientious in trying to provide information to the government," the spokesman said.

This article is copyrighted by Ibtimes.co.in.

    Click!
  • Rate this article:

Comments

Post Your Comment

You must be an IBTimes member to post a comment. Login | Register


advertisement
More Companies News
Toyota Motor Corp's surprise quarterly profit and halving of its annual loss forecast failed to convince investors the world's No.1 carmaker is back on t...
Tata Chemicals Ltd expects its fertiliser plant at Babrala in Uttar Pradesh to start commercial production by the middle of next year, a senior official ...
Microsoft Corp said on Wednesday it is cutting a further 800 jobs across its operations, on top of 5,000 jobs already eliminated under a plan to reduce c...

advertisement
 
IBTimes.co.in Web
 
International Business Times© 2009 The Ibtimes Company. All Rights Reserved. Partners